Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF "FLUMATINIB MESYLATE"

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") is pleased to announce that "flumatinib mesylate" (product name "**Hansoh Xinfu**" (豪森昕福)), a Category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People's Republic of China and obtained approval for marketing.

As a drug indicated for the treatment of Philadelphia chromosome-positive chronic adult patients with chronic myelogenous leukemia. Hansoh Xinfu is the first innovative drug with domestic independent intellectual property rights in its therapeutic area and was approved for marketing through the priority review and approval process. The approval for marketing of Hansoh Xinfu will provide a new drug choice for chronic adult patients with chronic myelogenous leukemia in the People's Republic of China.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, November 27, 2019

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.